Pharmacokinetic modelling of [2-13C]uracil metabolism in normal and DPD-deficient dogs

M Inada; Y Hirao; T Koga; M Itose; J Kunizaki; T Shimizu; H Sato

doi:10.1080/15257770600894550

Pharmacokinetic modelling of [2-13C]uracil metabolism in normal and DPD-deficient dogs

Nucleosides Nucleotides Nucleic Acids. 2006;25(9-11):1205-9. doi: 10.1080/15257770600894550.

Authors

M Inada¹, Y Hirao, T Koga, M Itose, J Kunizaki, T Shimizu, H Sato

Affiliation

¹ Research Section, Diagnostics Division, Otsuka Pharmaceutical Co Ltd, Japan. [email protected]

PMID: 17065092
DOI: 10.1080/15257770600894550

Abstract

A physiologically based pharmacokinetic (PBPK) model to simulate the plasma concentration and 13CO2 exhalation after [2-13C]uracil administration to DPD-suppressed dogs was developed. Simulation using this PBPK model should be useful in clinical situations where DPD-deficient patients at risk are to be detected with [2-13C]uracil as an in vivo probe.

MeSH terms

Administration, Oral
Animals
Breath Tests
Carbon Dioxide / chemistry
Carbon Isotopes / metabolism*
Computer Simulation
Dihydropyrimidine Dehydrogenase Deficiency*
Dihydrouracil Dehydrogenase (NADP) / biosynthesis*
Dihydrouracil Dehydrogenase (NADP) / chemistry
Dogs
Kinetics
Models, Biological
Models, Chemical
Models, Theoretical
Time Factors
Uracil / blood*
Uracil / chemistry*
Uracil / pharmacokinetics*

Substances

Carbon Isotopes
Carbon Dioxide
Uracil
Dihydrouracil Dehydrogenase (NADP)